JP2023501347A5 - - Google Patents

Info

Publication number
JP2023501347A5
JP2023501347A5 JP2022526035A JP2022526035A JP2023501347A5 JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5 JP 2022526035 A JP2022526035 A JP 2022526035A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5
Authority
JP
Japan
Prior art keywords
sequence
antisense oligomer
fcεriβ
exon
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059682 external-priority patent/WO2021092562A1/en
Publication of JP2023501347A publication Critical patent/JP2023501347A/ja
Publication of JP2023501347A5 publication Critical patent/JP2023501347A5/ja
Pending legal-status Critical Current

Links

JP2022526035A 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ Pending JP2023501347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (2)

Publication Number Publication Date
JP2023501347A JP2023501347A (ja) 2023-01-18
JP2023501347A5 true JP2023501347A5 (https=) 2023-11-16

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526035A Pending JP2023501347A (ja) 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ

Country Status (6)

Country Link
US (1) US20220380777A1 (https=)
EP (1) EP4054639A4 (https=)
JP (1) JP2023501347A (https=)
CN (1) CN115335078A (https=)
AU (1) AU2020378207A1 (https=)
WO (1) WO2021092562A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
CN120019145A (zh) * 2022-09-28 2025-05-16 阿塔兰塔治疗公司 用于治疗神经炎性疾病的组合物和方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
EP2933332A1 (en) * 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP2290087A3 (en) * 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
EP3841198A4 (en) * 2018-04-13 2022-03-02 Rene Anand REAGENTS AND METHODS FOR AUTISM AND ITS COMORBIDITIES

Similar Documents

Publication Publication Date Title
JP2023501347A5 (https=)
US20200291407A1 (en) Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
AU2018318135B2 (en) Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
US8946183B2 (en) Compositions and methods for modulation of SMN2 splicing
JP2022523302A (ja) アッシャー症候群の処置のためのｒｎａ編集オリゴヌクレオチド
ES2600356T3 (es) Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
BR112020007881A2 (pt) Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense
TW201210611A (en) Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT
KR20080031164A (ko) ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
JP2024537991A5 (https=)
JP2019500347A5 (https=)
TW201219569A (en) Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CA2785727A1 (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
TW201209163A (en) Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
Slavov et al. Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns
JPWO2018164275A1 (ja) アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
US20240254488A1 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
JP2023542889A5 (https=)
US12529057B2 (en) Therapeutics for Syngap haploinsufficiency
JP2021534799A5 (https=)
CN115103911A (zh) 修饰的异源核酸
JPH09501057A (ja) 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節
JP2022546408A5 (https=)
JP2004524801A5 (https=)